Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XPro1595 in Early Alzheimer’s Disease with Inflammation Biomarkers
2023-505396-71-00Phase 2Completed
- Sponsor
- INmune Bio Inc.
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing XPro1595 with Placebo (2 arms). Primary endpoint: Change in EMACC from Baseline to Week 24. Started Mar 2024; status: completed.
02
Drugs
pegipanermin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2023-505396-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505396-71-00.